Table 1.

Evidence of TMB as a biomarker in clinical trial.

Tumour type		Testing drug	TMB method	TMB cutoff	Type of benefit
NSCLC	Checkmate 026	Nivolumab	WES	>243 mut/exome	ORR, PFS
	Rozenblum et al, 2017	Nivolumab or pembrolizumab	FoundationOne	>9,6 mut/Mb	ORR
	KEYNOTE 001	Pembrolizumab	WES	>178 mut/exome	ORR, PFS
	POPLAR/OAK	Atezolizumab	Foundation bTMB	>10 mut/Mb	PFS, OS
	POPLAR/FIR/BIRCH	Atezolizumab	FoundationOne	1st line: >13,5 mut/Mb 2nd line: >17,1 mut/Mb	ORR, PFS, OS
	BFAST and BF1RST	Atezolizumab	Foundation bTMB	Unknown	ORR, PFS, OS
	MSKCC, Rizvi et al, 2018	Multiagent (alone or in combination)	WES	>8,5 mut/Mb	ORR, PFS
	Checkmate 227	Ipilimumab + nivolumab	FoundationOne	>10 mut/Mb	ORR, PFS
	Checkmate 568	Ipilimumab + nivolumab	FoundationOne	>10 mut/Mb	ORR, PFS
	Checkmate 012	Ipilimumab + nivolumab	WES	>158 mut/exome	ORR, PFS and clinical benefit
Melanoma	Checkmate 064	Nivolumab	WES	Unknown	ORR, OS
	Van Allen et al 2015	Ipilimumab	WES	197 mut/exome	Clinical benefit
	Snyder et al 2014	Ipilimumab	WES	>100 mut/exome	OS
	Johnson et al, 2016	Multiagent (alone or in combination)	FoundationOne	>23,1 mut/Mb	ORR, PFS, OS
	Hugo et al, 2016	Multiagent (alone or combination)	WES	>495 mut/exome	OS
	Checkmate 038	Nivolumab	WES	>100 mut/exome	OS
Bladder	Checkmate 275	Nivolumab	WES	>167 mut/exome	ORR, PFS, OS
	Imvigor 210	Atezolizumab	FoundationOne	>16 mut/Mb	ORR, OS
	Imvigor 211	Atezolizumab	FoundationOne	> median	OS
	Snyder et al, 2017	Atezolizumab	WES	> median	PFS
SCLC	Hellman et al, 2018	Nivolumab + ipilimumab	WES	>248 mut/exome	ORR, PFS, OS
CRC	KEYNOTE 012 - 028	Pembrolizumab	WES	Unknown	ORR, PFS
Multiple solid tumours	Goodman et al, 2017	Multiagent (alone or combination)	FoundationOne	>20 mut/Mb	ORR, PFS, OS
	Yarchoan et al, 2017	Multiagent (alone or combination)	Various	Various	ORR